Torque Teno Virus (TTV) in Renal Transplant Recipients: Species Diversity and Variability.

Torque Teno Virus (TTV) is a nonpathogenic and ubiquitous ssDNA virus, a member of the Anelloviridae family. TTV has been postulated as a biomarker in transplant patients. This study aimed to determine the TTV species diversity and variability in renal transplant recipients and to associate species diversity with the corresponding TTV viral load. From 27 recipients, 30 plasma samples were selected. Viral load was determined using two real-time PCR assays, followed by RCA-NGS and ORF1 phylogenetic analysis. The TTV diversity was determined in all samples. Variability was determined in three patients with two sequential samples (pre- and post-transplantation). Most of the samples presented multiple TTV species, up to 15 different species were detected. In the pre-transplant samples (n = 12), the most prevalent species were TTV3 (75%) and TTV13 (75%), and the median number of species per sample was 5 (IQR: 4-7.5). TTV3 was also the most prevalent (56%) in the post-transplant samples (n = 18), and the median number of species was 2 (IQR: 1.8-5.5). No significant correlation between the number of species and viral load was found. The number and type of TTV species showed total variability over time. We report high TTV species diversity in Argentinian recipients, especially in pre-transplant period, with total intra-host variability. However, we found no significant correlation between this high diversity and TTV viral load.

Access to treatment in chronic kidney disease, dialysis and transplantation. Is there gender equality?

Sex and gender are often used as synonyms. However, while sex describes only a biological state, gender is a dynamic concept that takes into account psychosocial and cultural aspects of human existence that can change according to place and time. Inequality in medicine has been described in several areas. Among them, gender inequality has been disregarded for many years and is now a matter of concern. Chronic kidney disease (CKD) is a growing epidemic worldwide, affecting approximately 10% of the population. Although both men and women are affected, gender equality, especially in access to different treatments, is a matter of concern. We decided to investigate gender equality in patients with CKD. To this end, we conducted a literature narrative review to determine whether gender inequalities were found in CKD patients in general and in access to different treatment modalities in particular. A non-language restricted search was performed until November 30th 2022 in PubMed, SciELO, Trip Database, Google Scholar, MEDES y MEDLINE. We also investigated the situation in this regard in our country. We found that CKD is more prevalent in women than men, nevertheless this prevalence decreases along the CKD stages to the point that more men reach end stage kidney disease (ESKD) and dialysis. Access to transplant (ATT) is higher in men than in women although posttransplant survival shows no gender differences. Finally, most series have shown that women are more frequently Kidney transplantation (KT) living donors than men. Results in our country are similar to the published literature with the exception of a higher proportion of men as KT living donors. As in other areas, gender inequality in Nephrology has been largely overlooked. In this review we have highlighted gender differences in CKD patients. Gender inequality in Nephrology exists and needs to be looked upon in order to reach a personalized clinical approach.

Renal Transplantation in the Elderly: Are They All the Same? A Multicenter, Comorbidity-Based Study.

INTRODUCTION: The age for kidney transplantation (KT) is no longer a limitation and several studies have shown benefits in the survival of elderly patients. The aim of this study was to examine the relationship of the baseline Charlson comorbidity index (CCI) score to morbidity and mortality after transplantation. METHODS: In this multicentric observational retrospective cohort study, we included patients older than 60 years admitted on the waiting list (WL) for deceased donor KT from January 01, 2006, to December 31, 2016. The CCI score was calculated for each patient at inclusion on the WL. RESULTS: Data for analysis were available of 387 patients. The patients were divided in tertiles of CCI: group 1 (CCI: 1-2) n = 117, group 2 (CCI: 3-4) n = 158, and group 3 (CCI: ≥5) n = 112. Patient survival was significantly different between CCI groups at 1, 3, and 5 years, respectively: 90%, 88%, and 84% for group 1, 88%, 80%, and 72% for group 2, and 87%, 75%, and 63% for group 3 (p < 0.0001). Variables associated with mortality were CCI score (p < 0.0001), HLA mismatch (p = 0.014), length of hospital stay (p < 0.0001), surgical complications (p = 0.048). CONCLUSION: Individualized strategies to modify these variables may improve patient's morbidity and mortality after KT.

Early start hemodialysis with a catheter may be associated with greater mortality: A propensity score analysis.

INTRODUCTION: Deciding when and how to initiate hemodialysis (HD) is still controversial. An early start (ES) seems to show a lack of benefit. "Lead time bias" and comorbidities have been associated with different outcomes in ES groups. On the other hand, it is well accepted that the impact the type of vascular access (VA) has on patient survival. Our aim was to evaluate survival with early start (ES) versus late start (LS) on HD, taking into account the vascular access (VA) used. METHODS: Between 01/1995 and 06/2018, 503 incidental patients initiated HD at our Dialysis Unit. eGFR was estimated by the CKD-EPI equation. Diabetes mellitus (DM), coronary disease (CD), and peripheral vascular disease (PVD) were considered comorbid conditions. According to eGFR and VA, patients were divided into four groups: G1: ES (eGFR > 7 mL/min) with catheter (ES + C), G2: ES with fistula or graft (F/G) (ES + F/G), G3: LS (eGFR< 7 mL/min) with catheter (LS + C), and G4: LS with F/G (LS + F/G). The cut-off value to define ES or LS was based on median eGFR for these 503 patients. We compared patient's survival rates by Kaplan-Meier and log-rank test. The four groups were compared before and after matching with propensity scores (PS). Cox analysis was performed to determine the impact of predictors of mortality. RESULTS: Median eGFR was 7 (5.3-9.5) mL/min/1.73 m2 , median follow-up time was 30.9 (13-50) months, 52.1% had F/G access at entry, and 46.9% died during the observation period. Among the four groups, the ES + C were significantly older, and there were more diabetics and comorbid conditions, while phosphatemia, iPTH, albumin, and hemoglobin were significantly higher in the LS groups. Before propensity score (PS) matching, the ES + C group had a poor survival rate (p < 0.0001), while LS + F/G access had the best survival. After PS, a total of 180 patients were selected in the same four groups and ES + C kept showing a statistically significant poorer survival. Multivariate analysis revealed that ES + C was an independent predictor of mortality. CONCLUSION: In this retrospective study, ES + C on HD was associated with a higher mortality rate than LS. This association persisted after PS matching.

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients.

BACKGROUND AND AIM: Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. The vaccination scheme depended on dose availability and the prioritization of risk populations as established by the Argentine Ministry of Health. METHODS: Previous COVID-19 infection was determined in symptomatic patients. Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2 (anti-S-RBD) concentration was assessed between 3 and 16 weeks after the boost dose. Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20-136. Following the manufacturer's recommendations, samples were considered reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as mild = 1-2, moderate = 3-4, and severe ≥ 5. Side effects were evaluated until day 7 by patients´ self-reported questionnaire. RESULTS: One hundred seven participants were enrolled [n = 84 homologous (SpV/SpV), nn 23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50-75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection (p = 0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288-5680) BAU/mL] than in the homologous scheme [447 (100-1551) BAU/mL], p = 0.022. In a linear model adjusted for age, gender, days from first vaccination to boost dose and days from the boost dose to the anti-S-RBD IgG determination, previous SARS-COV-2 infection (B: 2062.2; CI95: 1231.8-2892.6; p < 0.001), and SpV/Mod vaccination scheme (B: 1294.6; CI95: 435.58-2147.6; p = 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. CONCLUSIONS: The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good efficacy and safety in patients on chronic dialysis. These results could be useful for designing future vaccination strategies, especially aimed at this risk group.

Assessing Renal Function for Kidney Donation. How Low Is Too Low?

Kidney transplantation (KT) is the treatment of choice for patients with end-stage kidney disease (ESKD) with decreased morbi-mortality, improved life quality, and reduced cost. However, the shortage of organs from deceased donors led to an increase in KT from living donors. Some stipulate that living donors have a higher risk of ESKD after donation compared with healthy non-donors. The reason for this is not clear. It is possible that ESKD is due to the nephrectomy-related reduction in glomerular filtration rate (GFR), followed by an age-related decline that may be more rapid in related donors. It is essential to assess donors properly to avoid rejecting suitable ones and not accepting those with a higher risk of ESKD. GFR is a central aspect of the evaluation of potential donors since there is an association between low GFR and ESKD. The methods for assessing GFR are in continuous debate, and the kidney function thresholds for accepting a donor may vary according to the guidelines. While direct measurements of GFR (mGFR) provide the most accurate evaluation of kidney function, guidelines do not systematically use this measurement as a reference. Also, some studies have shown that the GFR decreases with age and may vary with gender and race, therefore, the lower limit of GFR in patients eligible to donate may vary based on these demographic factors. Finally, it is known that CrCl overestimates mGFR while eGFR underestimates it, therefore, another way to have a reliable GFR could be the combination of two measurement methods.

Seroprevalence of hepatitis B, hepatitis C and HIV infection among patients undergoing haemodialysis in Buenos Aires, Argentina.

Introduction. Blood-borne infections are a major cause of harm in individuals on haemodialysis (HD). In particular, knowledge about hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) status in HD patients is a major concern, since these infections may cause comorbidities in this setting. There is a paucity of data regarding this issue in Argentina.Hypothesis/Gap Statement. The epidemiological surveillance of HBV, HCV, and HIV is a fundamental tool for planning and implementing health strategies in order to prevent and control viral transmission of these viral agents.Aim. To determine the seroprevalence of HBV, HCV and HIV infections in HD patients in Buenos Aires, Argentina.Methodology. Seven hundred and forty-eight HD patients were included in a retrospective cross-sectional study. Serological assays were performed to determine HBV, HCV and HIV status. HBV HBsAg and anti-HBc IgG were analysed using AxSYM (samples before 2010) or the Architect Abbott system (samples since 2010), anti-HCV IgG testing was performed using the anti-HCV enzyme immunoassay AxSYM HCV V3.0 and ARCHITECT anti-HCV, while HIV was tested for using AxSYM HIV 1/2 gO and ARCHITECT HIV Ag/Ab Combination. HCV genotyping was carried out by phylogenetic analysis of the NS5B partial gene.Results. Infection with one of the viruses was detected in 31.1 % of patients [HBV in 82 (11.0 %), HCV in 179 (23.9 %) and HIV in 6 (0.8 %)]. Thirty-two (4.3 %) patients had 2 virus markers [27 (3.6 %) with HCV/HBV, 4 (0.5 %) with HCV/HIV and 1 (0.13 %) with HBV/HIV]. Finally, a single patient (0.13 %) presented all three markers. Time on dialysis was correlated with HCV but not with HBV infection. The HCV subtype distribution in HD patients was inverted with respect to that observed in the general population (HCV-1a 73.2 % and HCV-1b 26.8 % in HD vs HCV-1a 26.5 % and HCV-1b 73.5 % in the general population, P <0.001).Conclusion. Despite the implementation of universal precautionary biosafety standards for dialysis, infection with HBV and HCV continues to occur at very high rates in HD patients. The results emphasize the need to carry out proactive tasks for early diagnosis and treatment of infected individuals and to vaccinate those with non-protective antiHBs antibodies in order to reduce morbidity and mortality in HD patients.

Increased miR-7641 Levels in Peritoneal Hyalinizing Vasculopathy in Long-Term Peritoneal Dialysis Patients.

Peritoneal hyalinizing vasculopathy (PHV) represents the cornerstone of long-term peritoneal dialysis (PD), and especially characterizes patients associated with encapsulating peritoneal sclerosis. However, the mechanisms of PHV development remain unknown. A cross sectional study was performed in 100 non-selected peritoneal biopsies of PD patients. Clinical data were collected and lesions were evaluated by immunohistochemistry. In selected biopsies a microRNA (miRNA)-sequencing analysis was performed. Only fifteen patients (15%) showed PHV at different degrees. PHV prevalence was significantly lower among patients using PD fluids containing low glucose degradation products (GDP) (5.9% vs. 24.5%), angiotensin converting enzyme inhibitors (ACEIs) (7.5% vs. 23.4%), statins (6.5% vs. 22.6%) or presenting residual renal function, suggesting the existence of several PHV protective factors. Peritoneal biopsies from PHV samples showed loss of endothelial markers and induction of mesenchymal proteins, associated with collagen IV accumulation and wide reduplication of the basement membrane. Moreover, co-expression of endothelial and mesenchymal markers, as well as TGF-ß1/Smad3 signaling activation were found in PHV biopsies. These findings suggest that an endothelial-to-mesenchymal transition (EndMT) process was taking place. Additionally, significantly higher levels of miR-7641 were observed in severe PHV compared to non-PHV peritoneal biopsies. Peritoneal damage by GDPs induce miRNA deregulation and an EndMT process in submesothelial vessels, which could contribute to collagen IV accumulation and PHV.

Renal Transplantation in Patients Older Than 60 Years With High Comorbidity. Is There a Survival Benefit? A Multicenter Study in Argentina.

BACKGROUND: The impact of renal transplantation (RT) in the elderly with many comorbid conditions is a matter of concern. The aim of our study was to assess the impact of RT on the survival of patients older than 60 years compared with those remaining on the waiting list (WL) according to their comorbidities. METHODS: In this multicentric observational retrospective cohort study, we included all patients older than 60 years old admitted on the WL from 01 January 2006 to 31 December 2016. The Charlson comorbidity index (CCI) score was calculated for each patient at inclusion on the WL. Kidney donor risk index was used to assess donor characteristics. RESULTS: One thousand and thirty-six patients were included on the WL of which 371 (36%) received an RT during a median follow-up period of 2.5 (1.4-4.1) years. Patient survival was higher after RT compared to patients remaining on the WL, 87%, 80%, and 72% versus 87%, 55%, and 30% at 1, 3, and 5 years, respectively. After RT survival at 5 years was 37% higher for patients with CCI ≥ 3, and 46% higher in those with CCI < 3, compared with patients remaining on the WL. On univariate and multivariate analysis, patient survival was independently associated with a CCI of ≥3 (hazard ratio 1.62; confidence interval 1.09-2.41; P < 0.02) and the use of calcineurin-based therapy maintenance therapy (hazard ratio 0.53; confidence interval 0.34-0.82; P < 0.004). CONCLUSIONS: Our study showed that RT improved survival in patients older than 60 years even those with high comorbidities. The survival after transplantation was also affected by comorbidities.

Reduced survival in patients who return to dialysis after kidney allograft failure.

BACKGROUND: The outcome of patients who return to dialysis after Kidney allograft failure (KAF) remains unclear. Our aim was to compare the outcome of KAF patients vs two different types of transplant naive incident dialysis (TNID) patients, those on the waiting list (WL) and those with a kidney transplant contraindication (KTC). METHODS: We performed an observational study using data from the Argentinian Dialysis Registry between 2005 and 2016. We compare mortality between KAF, WL, and KTC. RESULTS: We included 75 722 patients of which 2734 were KAF. Survival between the three cohorts (KAF vs WL (n = 14 630) vs KTC (n = 58 358) revealed a significant difference (log-rank test: P < .0001) indicating worse survival for KTC patients and best survival for WL. We found that KAF patients had as poor outcome as KTC patients after multivariate adjustment. Cox regression showed that age >65 years: HR: 1.845 (1.79-1.89) P < .0001, transient catheter: HR: 1.303 (1.26-1.34) P < .0001, diabetic: HR: 1.273 (1.22-1.31) P < .0001, hepatitis C: HR: 1.156 (1.09-1.22) P < .0001, and albumin: HR: 1.247 (1.21-1.28) P < .0001 were associated with mortality. CONCLUSION: Patients who return to dialysis after KAF have higher mortality than WL patients and similar to KTC patients.

Litiasis renal y riesgo cardiovascular / Nephrolithiasis and cardiovascular risk

La litiasis renal es una enfermedad frecuente cuya prevalencia ha aumentado en los últimos años. En la actualidad se la considera como una patología sistémica; no limitada al riñón y a las vías urinarias, sino relacionada en gran medida a diabetes mellitus, obesidad, hipertensión arterial, hiperuricemia, hipercolesterolemia y enfermedad renal crónica, todos factores de riesgo cardiovascular que suelen vincularse a eventos severos como accidentes cerebrovasculares, enfermedad coronaria o infarto agudo de miocardio. Numerosos estudios transversales y meta-análisis han demostrado la asociación entre estas dos entidades. En esta revisión intentaremos demostrar los mecanismos involucrados en la fisiopatología de la litiasis renal y su relación con enfermedad cardiovascular. Como mecanismos involucrados, se mencionan tres asociaciones. La primera se refiere al estrés oxidativo y la inflamación. La segunda asociación se refiere a la presencia de mecanismos litogénicos que contribuyen a la calcificación vascular. Como última teoría se realiza la asociación ya conocida, de obesidad, síndrome metabólico, diabetes e hipertensión arterial, todos factores de riesgo para el desarrollo de litiasis renal así como de enfermedad cardiovascular, recordando que la litiasis renal es causa, en un 8%, del desarrollo de enfermedad renal crónica, otro factor de riesgo para enfermedad y muerte cardiovascular. Como conclusión se confirma la teoría de que la litiasis renal no es una enfermedad limitada al riñón y la vía urinaria, si no que se trata de una enfermedad sistémica, con riesgo de eventos cardiovasculares tan severos que pueden llevar a la muerte.

Renal lithiasis is a frequent disease whose prevalence has increased in recent years. Nowadays it is considered as a systemic pathology, not limited to the kidney and the urinary tract, but largely related to diabetes mellitus, obesity, hypertension, hyperuricemia, hypercholesterolemia and chronic kidney disease; all cardiovascular risk factors that are usually linked to severe events such as stroke, coronary heart disease or acute myocardial infarction. Numerous cross-sectional studies and meta-analyzes have proved the association between renal lithiasis and cardiovascular disease. In this review we will try to demonstrate the mechanisms involved in the pathophysiology of these two entities. Three associations are mentioned. The first one refers to oxidative stress and inflammation. The second association refers to the presence of lithogenetic mechanisms contributing to vascular calcification. The last theory is the already known correlation with obesity, metabolic syndrome, diabetes and hypertension; all risk factors for the development of renal lithiasis as well as cardiovascular disease. Let us remember that renal lithiasis is the cause, in 8% of cases, of the development of chronic kidney disease, another risk factor for cardiovascular disease and death. In conclusion, the theory that renal lithiasis is not a disease limited to the kidney and the urinary tract is confirmed; it is rather a systemic disease, with a risk of cardiovascular events so severe that they can lead to death.

Predictores de fuerza de presión palmar en hemodiálisis en un centro único en Argentina / Predictors of handgrip strength in hemodialysis patients at a single center in Argentina

INTRODUCCIÓN: Existe una alta incidencia de fracturas en pacientes con enfermedad crónica terminal. Esto se debe en parte a la enfermedad óseo mineral del enfermo renal crónico y en parte a la alta prevalencia de debilidad muscular en esta población. OBJETIVO: Nuestro objetivo fue evaluar cuáles son los determinantes de fuerza muscular medida por fuerza de prensión palmar (FPP) en nuestra población de pacientes en hemodiálisis crónica. MATERIAL Y MÉTODOS: Estudio de corte transversal en adultos de un centro de hemodiálisis. Se registró la FPP y el índice de masa magra (IMM). Se registraron los valores de albumina, magnesio y otros parámetros serológicos. Utilizamos un análisis de regresión lineal múltiple para evaluar los predictores de FPP. RESULTADOS: Analizamos 139 pacientes (hombres: mujeres = 88:51, edad 60.7 ± 16), 18 fueron excluidos. La media de albúmina: 3.8 +/- 0.47 mg/dl, la mediana de tiempo en hemodiálisis: 37 meses (15-83), 25% (n= 35) fueron definidos como sarcopénicos y 21.5% (n= 30) tenían antecedentes de diabetes. En el análisis univariado el magnesio presentó correlación positiva con la FPP (ß 0.19 p 0.02). En el análisis multivariado todas las siguientes continuaron siendo correlativas con la FPP y estadísticamente significativas (R2 0.61 p <0.001): albumina (ß:.4.36 p 0.02), IMM (ß: 1.44 p <0.001), edad (ß -0.10 p 0.04), sexo (ß 6.21 p 0.007), diabetes (ß -5,08 p 0.005). CONCLUSIÓN: Edad, diabetes, albúmina, sexo e IMM están independientemente asociados con la FPP en pacientes en hemodiálisis. Los niveles séricos de magnesio presentaron asociación en el análisis univariado

INTRODUCTION: There is a great incidence of fractures in patients suffering from end-stage chronic disease. This is partly caused by chronic kidney disease-mineral bone disorder and partly by the high prevalence of muscle weakness in these patients. OBJECTIVE: Our objective was to identify the determining factors of muscle strength measured by means of handgrip strength (HGS) in chronic hemodialysis patients. METHODS: A cross-sectional study was conducted on adult patients in a hemodialysis center. Handgrip strength (HGS) and lean mass index (LMI) were measured, as well as albumin and magnesium values and other serological parameters. Multiple linear regression was used to assess HGS predictors. RESULTS: We analyzed 139 patients (88 men and 51 women; age: 60.7 ± 16); 18 subjects were excluded. Mean albumin values: 3.8 +/- 0.47 mg/dL; median hemodialysis time: 37 months (15-83). From the total number of patients, 25% (n=35) were found to be sarcopenic and 21.5% (n=30) had a history of diabetes. The univariate analysis showed a positive correlation between magnesium and HGS (ß 0.19 p 0.02). According to the multivariate analysis, all the following showed a correlation with HGS and were statistically significant: (R2 0.61 p <0.001): albumin (ß:.4.36 p 0.02); LMI (ß: 1.44 p <0.001); age (ß -0.10 p 0.04); sex (ß 6.21 p 0.007); diabetes (ß -5,08 p 0.005). CONCLUSION: Age, diabetes, albumin values, sex and LMI are independently associated with HGS in hemodialysis patients. Serum magnesium levels showed an association in the univariate analysis

¿Es la Hemodialfiltración On-line de alto volumen el mejor tratamiento en pacientes con enfermedad renal crónica estadio V? / Is High-Volume On-line Hemodiafiltration the best treatment for patients with Chronic Kidney Disease Stage V?

INTRODUCCIÓN: La hemodiafiltración en línea de alto volumen (HVHDF) es una técnica eficaz que permite la remoción de toxinas urémicas de mayor PM debido al transporte convectivo. Esta modalidad permite mayor estabilidad hemodinámica, disminución de los parámetros inflamatorios y reducción de la mortalidad cardiovascular y por todas las causas comparada con la hemodiálisis (HD). Estos beneficios se producen cuando los volúmenes de sustitución (VS) son mayores a 21 L/sesión de allí la denominación de hemodiafiltración de alto volumen. OBJETIVOS: Evaluar la eficacia de la HVHDF en comparación con HD y determinar si el cambio de modalidad se asocia a mayor estabilidad hemodinámica, mejoría en los resultados de laboratorio, en la cantidad de hospitalizaciones y en la calidad de vida. MATERIAL Y MÉTODOS: Estudio retrospectivo, observacional, en único centro que incluyó 53 pacientes, que completaron 6 meses de HVHDF luego de haber realizado al menos 6 meses de HD. Se analizaron datos demográficos, episodios de hipotensión, número y días de internación tanto en HD como en HVHDF. Se compararon: Hemoglobina (Hb), fósforo (P), parathormona intacta (PTHi), albúmina (alb), proteína C reactiva (PCR), KTV, y dosis de eritropoyetina durante el último mes de HD y sexto mes de HVHDF. Se analizó la encuesta sobre calidad de vida Kidney Disease Quality of Life-36 (KDQOL-36) al inicio y a los 6 meses de HVHDF. RESULTADOS: LA edad media fue de 60,6 años, el 67.9 % eran hombres. La FAV fue el acceso vascular en el 69.8% de los pacientes, mientras que 38 pacientes (71,1%) cumplían con volumen de sustitución > 21 litros/sesión. El 39,6 % presentó algún episodio de hipotensión en HD y 30.2 % lo hizo en HVHDF (p<0.001). El número de episodios de hipotensión fue significativamente mayor en hemodiálisis que en HVHDFL, 40 (18-68) vs 11 (3-33) (p< 0.001). El 32% de pacientes en HD requirió internación y sólo el 11% en HVHDF. Hubo mejoría significativa en la Hb: 10.7 a 11.3 (p<0.01), KTV: 1.4 a 1.5 (p<0.03) y menor requerimiento de EPO (p< 0,02) al 6° mes de HVHDF. En la encuesta de calidad de vida, KDQOL-36, se observó mejoría en el módulo, síntomas problemas, siendo estadísticamente significativo, adicionándose mejoría en short form 12 (SF) físico y mental sólo en los pacientes con volúmenes de sustitución > 21l/sesión. CONCLUSIÓN: En nuestra cohorte el cambio de HD a HVHDF se asoció a una disminución en el número de episodios de hipotensión, reflejando una mayor estabilidad hemodinámica, menor número de internaciones, una mejoría en la hemoglobina, KTV y disminución de dosis semanal de eritropoyetina

INTRODUCTION: High-volume online hemodiafiltration (HV-OL-HDF) is an effective technique to remove uremic toxins with higher molecular weight through convective transport. In correlation with hemodialysis (HD), through this method, greater hemodynamic stability, lower inflammatory parameters and a smaller risk of death due to cardiovascular or any other factors are achieved. These benefits are obtained when substitution volume (SV) is higher than 21L/session; that is the reason why the technique is called high-volume hemodiafiltration (HVHDF). OBJECTIVES: To assess the effectiveness of HVHDF as compared to HD and to determine if changing the type of therapy results in greater hemodynamic stability, better lab test results, a lower number of hospital admissions and a superior quality of life. METHODS: This retrospective observational study was conducted in only one center and included 53 patients who underwent HVHDF during 6 months after having hemodialysis (HD) for at least 6 months. We analyzed demographic variables, number of hypotension events, number of hospital admissions, and length of stay for each type of treatment. The following were compared: hemoglobin (Hb), phosphate (P), intact parathormone (iPTH), albumin (ALB), C-reactive protein (CRP), Kt/V and erythropoietin dose during the last month of HD and the sixth month of HVHDF. The Kidney Disease Quality of Life-36 (KDQOL-36™) questionnaire was completed at the beginning and after 6 months of HVHDF. RESULTS: The average age was 60.6 years old and 67.9% of the participants were men. The vascular access was created using an arteriovenous fistula in 69.8% of patients and 38 of them (71.1%) had substitution volume of > 21L/session. Some patients (39.6 %) experienced a hypotension event during HD and others (30.2%) during HVHDF (p<0.001). The number of hypotension events was significantly higher in patients treated with HD than in patients treated with HV-OL-HDF: 40 (18-68) vs. 11 (3-33) (p< 0.001). The percentage of patients admitted to hospital was the following: 32% for HD and 11% for HVHDF. A considerable improvement was observed in Hb (10.7 to 11.3 [p<0.01]) and Kt/V (1.4 to 1.5 [p<0.03]; a lower dose of EPO was needed after 6 months of HVHDF (p< 0.02). Only patients with substitution volume of > 21L/session showed statistically significant improvement in the symptoms/problems section of KDQOL-36 and in the Short Form-12 (SF-12) Physical and Mental Health Summary. CONCLUSION: When changing from HD to HVHDF, our study group had a lower number of hypotension events; greater hemodynamic stability; a smaller number of hospital admissions; better Hb levels and Kt/V, and they needed a lower dose of erythropoietin

Prevalence of factors related to vascular calcifications in patients with chronic kidney disease on dialysis.

The main aim of the study was to determine the prevalence of vascular calcifications in patients with chronic kidney disease on dialysis in our population assessed by X-ray. The secondary objectives were to determine the cardiovascular risk factors associated with the presence of vascular calcifications and to evaluate the complementary use of the echocardiogram in a cross-sectional, observational, multicentric study. We included patients with chronic kidney disease on dialysis, age =18 years with at least 3 months of renal replacement therapy in 8 dialysis centres in Argentina. The degree of vascular calcification was determined using Adragao and Kauppila scores. The presence of valvular calcifications was established through a trans-thoracic doppler echocardiogram. Univariate and multivariate analysis were undertaken, considering the degree of vascular calcification as the dependent variable; 443 adult patients were evaluated at 8 centres across 5 provinces in Argentina. The prevalence of vascular calcifications by the X-rays was 63%, while 73% presented calcifications in hands and pelvis, with an Adragao score > 3, and 60% presented calcifications in the abdominal aorta with a Kauppila score > 4. The prevalence of valvular calcifications: 28%. We have shown a higher rate of vascular calcifications with the use of plain X-rays when compared to the prevalence of valvular calcifications obtained with echocardiograms. In this regard, valvular calcifications were present particularly in those patients with a severe level of radiological vascular calcification.

Prevalence of factors related to vascular calcification in patients with chronic kidney disease on dialysis

The main aim of the study was to determine the prevalence of vascular calcifications in patients with chronic kidney disease on dialysis in our population assessed by X-ray. The secondary objectives were to determine the cardiovascular risk factors associated with the presence of vascular calcifications and to evaluate the complementary use of the echocardiogram in a cross-sectional, observational, multicentric study. We included patients with chronic kidney disease on dialysis, age =18 years with at least 3 months of renal replacement therapy in 8 dialysis centres in Argentina. The degree of vascular calcification was determined using Adragao and Kauppila scores. The presence of valvular calcifications was established through a trans-thoracic doppler echocardiogram. Univariate and multivariate analysis were undertaken, considering the degree of vascular calcification as the dependent variable; 443 adult patients were evaluated at 8 centres across 5 provinces in Argentina. The prevalence of vascular calcifications by the X-rays was 63%, while 73% presented calcifications in hands and pelvis, with an Adragao score >3, and 60% presented calcifications in the abdominal aorta with a Kauppila score >4. The prevalence of valvular calcifications: 28%. We have shown a higher rate of vascular calcifications with the use of plain X-rays when compared to the prevalence of valvular calcifications obtained with echocardiograms. In this regard, valvular calcifications were present particularly in those patients with a severe level of radiological vascular calcification.

El objetivo primario del estudio fue determinar la prevalencia de calcificaciones vasculares en pacientes con enfermedad renal crónica (ERC) en diálisis, a través de métodos accesibles y reproducibles. Como objetivo secundario: determinar los factores de riesgo cardiovascular asociados a la presencia de calcificaciones vasculares y evaluar la utilidad complementaria del ecocardiograma. Fue un estudio prospectivo, transversal y multicéntrico sobre pacientes prevalentes con ERC en diálisis. Se les realizaron radiografía de columna lumbar, de manos y panorámica de pelvis, para la determinación de las escalas de Adragao y Kauppila. La presencia de calcificaciones valvulares fue establecida por ecocardiograma doppler color transtorácico. Se obtuvieron los datos de 30 variables determinadas para el análisis uni y multivariado (regresión logística) de los factores de riesgo asociados. Se evaluaron 443 pacientes adultos de 8 centros de 5 provincias de la Argentina. La prevalencia de calcificaciones vasculares, determinada por las radiografías, fue 63%. La prevalencia de calcificaciones valvulares fue 28%. Las calcificaciones valvulares estuvieron presentes en aquellos pacientes con graves calcificaciones radiológicas. Las calcificaciones estuvieron asociadas a la edad (>55 años), sexo masculino, diabetes, tiempo de diálisis, tabaquismo y la presencia de enfermedad vascular periférica. Este es el estudio con mayor número de pacientes evaluados en Latinoamérica. Se encuentra alta prevalencia de calcificaciones vasculares en Argentina, fácilmente medibles con técnicas no invasivas como la radiografía simple, que resulta más sensible que el ecocardiograma. Ambos estudios deben ser utilizados de manera complementaria.

Nonprogrammed Vascular Access Is Associated With Greater Mortality in Patients Who Return to Hemodialysis With a Failing Renal Graft.

BACKGROUND: In incident hemodialysis (HD) patients, the use of catheters is associated with a worse prognosis when compared with those with an arteriovenous fistula, but the role of vascular access (VA) type in the morbidity and mortality of patients returning to HD with a failing renal allograft is unknown. We aimed to determine the associations between the type of VA and mortality in this population. METHODS: This was a retrospective observational cohort study of 138 patients who initiated dialysis after kidney transplant failure between 1995 and 2014. We recorded access type, laboratory values at entry, stratified patients per risk, and determined the effect on mortality of programmed VA (PVA), (arteriovenous fistula or PTFE graft) and nonprogrammed VA (UPVA) (tunneled or nontunneled catheters) at the initiation of HD. RESULTS: Eighty-five (61.6%) and 53 (38.4%) patients initiated therapy with PVA and UPVA, respectively. Overall mortality was 14.6% at 1 year. Patients using catheters had greater mortality than those with a PVA (log rank P <0.0001). At 24 months, 7 patients died in PVA group versus 22 in UPVA group. Multivariate Cox analysis showed that initiation of HD with a catheter (hazard ratio, 5.90; 95%, confidence interval, 2.83-12.31) was independently associated with greater mortality after adjusting for confounders. CONCLUSIONS: Nonprogrammed VA with a catheter predicted all-cause mortality among patients with transplant failure reentering HD.

Incidencia e impacto de Injuria Renal Aguda comunitaria e intrahospitalaria en un Hospital Universitario de Buenos Aires / Incidence and impact of community-acquired and hospital-acquired acute kidney injury at a Medical College Hospital in Buenos Aires

INTRODUCCIÓN: La IRA (Injuria Renal Aguda) es una condición prevalente en pacientes internados y se asocia a mayor número de complicaciones, estadía hospitalaria y mortalidad. A pesar de ser una patología ampliamente estudiada, carecemos de datos locales. OBJETIVOS:Determinar la incidencia de IRA en pacientes hospitalizados en un hospital polivalente, su impacto en mortalidad y tiempo de estadía hospitalaria. MATERIAL Y MÉTODOS: Realizamos un estudio de cohorte retrospectivo en pacientes mayores de 18 años de edad internados por razones médicas en sala general, unidades de cuidados críticos de los dos Hospitales Universitarios de CEMIC, durante los meses de marzo, abril y mayo del año 2013. Se definió IRA según los criterios de AKIN. Se estimó la mortalidad durante la internación y tiempo de estadía hospitalaria, tanto para el grupo con IRA como para el resto de los pacientes. Resultados: Se registraron 681 internaciones de las cuales 50 fueron excluidas por falta de datos, y 125 por enfermedad renal crónica estadio V o trasplante renal. El 52,2% del total fueron hombres, la mediana de edad fue de 69 años (56-79) y la mediana de creatinina fue de 0.89 mg/dl (0.7-1.06). La mortalidad global en internación fue de 42 casos (8.3%). De las internaciones incluidas (506) 82 presentaron AKIN I (60,3%), 25 AKIN II (18,3 %) y 29 AKIN III (21,3%). La incidencia global de IRA en el período fue de 26,9 %. La incidencia de IRA intrahospitalaria (IRA-IH) fue de 12,5%, en tanto que de IRA adquirida en la comunidad (IRA-AC) de 16,4%. Para el cálculo de la IRA-IH se excluyeron los pacientes que ingresaron con IRA-AC. La mediana de internación expresada en días en pacientes con IRA fue de 9,5 (5-17) y de 4 (2-8) en los pacientes sin IRA. El odds ratio (OR) de mortalidad asociado a IRA fue de 1,68 (IC: 0,98-2,88), pero discriminado según gravedad fue: para AKIN I 0,89 (IC: 0,39-2,05), AKIN II 1,37 (IC: 0,39-4,81) y AKIN III 20,95 (CI: 7,10-61,82). CONCLUSIÓN: La incidencia de IRA en pacientes hospitalizados por causas médicas, que hayan ingresado al Hospital por el Servicio de Medicina Interna, es de 26,9%. Haber cursado con IRA durante la internación se asocia con mayor mortalidad y mayor tiempo de estadía hospitalaria, hecho que condice con otros reportes

INTRODUCTION: Acute kidney injury (AKI) is a common condition among hospitalized patients and is associated with a higher number of complications and death rate, as well as with longer hospitalization periods. Despite being a widely studied pathology, no data have been collected within our local context. OBJECTIVES: To determine the incidence of AKI in patients at a general hospital, its impact on mortality and hospitalization period. METHODS: A retrospective cohort study was conducted on patients over 18 years old who had been admitted to the general ward or the intensive care unit at two CEMIC Medical College Hospitals from March to May 2013. AKI was defined according to the AKIN criteria. Death rate and hospitalization period were estimated for the AKI patients group and for the rest of the patients at these institutions. RESULTS: 681 cases were reported, 50 of which were excluded due to lack of information and 125 due to stage V chronic kidney disease or kidney transplant. 52.2% of subjects were men; the mean age was 69 (56-79), and the mean creatinine level was 0.89 mg/dL (0.7-1.06). Global mortality was of 8.3% (42 cases). Out of the total number of subjects (506), 82 met criteria for AKIN stage-1 (60.3%); 25, for AKIN stage-2 (18.3%), and 29, for AKIN stage-3 (21.3%). The global incidence of AKI during the period was of 26.9% [hospital-acquired AKI (HA-AKI) = 12.5% and community-acquired AKI (CA-AKI) = 16.4%]. To calculate the number of HA-AKI cases, the CA-AKI patients were not included. The average hospitalization period for AKI patients was 9.5 days (5-17) and 4 days (2-8) for the rest of them. The mortality odds ratio (OR) associated with AKI was of 1.68 (CI: 0.98-2.88), but depending on the severity of the condition, the OR values were: 0.89 (CI: 0.39-2.05) for AKIN stage-1; 1.37 (CI: 0.39-4.81) for AKIN stage-2, and 20.95 (CI: 7.10-61.82) for AKIN stage-3. CONCLUSION: The incidence of AKI in patients admitted to the Internal Medicine Service was of 26.9%. Suffering from AKI while hospitalized correlates with a higher death rate and a longer hospitalization period. These results are similar to those in other reports

Inicio urgente a diálisis peritoneal / Urgent-start on peritoneal dialysis

Introducción: la diálisis peritoneal es subutilizada en muchos países. Convencionalmente el ingreso de los pacientes agudos a terapia de reemplazo renal se hace a HD. El inicio urgente a diálisis peritoneal ofrece una opción segura y eficaz para evitar el uso de catéteres venosos centrales e incrementar el uso de Diálisis Peritoneal. Material y métodos: Es un estudio retrospectivo, observacional que comparan los pacientes que iniciaron diálisis peritoneal en forma urgente con los que iniciaron en forma convencional luego de 4 semanas. Resultados: Se analizaron 12 pacientes(n=12) ingresados a DP. Seis pacientes iniciaron en forma urgente y seis ingresaron en forma convencional. El tiempo de seguimiento fue menor para los pacientes de inicio urgente. No hubo diferencias significativas entre ambos grupos para: edad, sexo, volumen de inicio, KT/V, albúmina, urea, calcio, fósforo, ferritina, PCR y tipo de catéter. La PTH fue significativamente menor en los pacientes que iniciaron DP en forma urgente (P< 0,047). En cuanto a las complicaciones: dos pacientes presentaron fuga de líquido peritoneal y uno un hematoma de pared en el grupo de inicio urgente. Las complicaciones se resolvieron con tratamientos adecuados y no fueron causa de cambio de modalidad. Conclusiones: El inicio urgente a diálisis peritoneal es seguro y no conlleva a mayores complicaciones. Es una estrategia para disminuir el uso de catéteres de hemodiálisis e incrementar el número de pacientes en el programa de diálisis peritoneal.

Introduction: peritoneal dialysis is under-used in many countries. Usually the admission of acute patients to renal replacement therapy are directed to HD. Urgent start of peritoneal dialysis offers a safe and efficient option to avoid the use of central venous catheters and to increase peritoneal dialysis use. Material and methods: It is a retrospective, observational study comparing patients who started urgent peritoneal dialysis with those that started dialysis in the conventional way, after 4 weeks. Results: 12 peritoneal dialysis patients were analyzed. Six of them under urgent start and the other six received the conventional procedure, follow-up period was shorter for patients receiving urgent start. There were not significant differences between both groups concerning: age, sex, initial volume, KT/V, albumin, urea, calcium, phosphorus, ferritin, PCR and type of catheter. PTH was significantly lower in patients who received urgent start PD (P<0.047). Regarding complications: two patients presented leakage of peritoneal fluid and one patient had wall bruising, in the urgent start group. Complications were solved with adequate treatments and did not cause change of methods. Discussion: Urgent start to peritoneal dialysis is a safe method and does not involve major complications. It is a strategy to decrease the use of hemodialysis catheters and to increase number of patients on dialysis peritoneal programs.